6334 Winfield Boulevard
197 articles with Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that Troy Hamilton, Chief Executive Officer of Synergy, will present a corporate update at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m. Eastern Time at the Westin New York Grand Central in New York City.
Synergy Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Business Update
TRULANCE® U.S. net sales were $9.4 million in the fourth quarter, totaling $16.8 million for 2017.
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE from Synergy Pharmaceuticals
TRULANCE is a once-daily tablet approved by the U.S. Food and Drug Administration for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.
Synergy today announced that the Compensation Committee of the Board of Directors of Synergy approved the grant of inducement stock options to purchase 289,000 shares of Synergy common stock to 193 former contract sales representatives
Synergy today announced that it has met the cash balance requirement to access additional capital under the Term Loan Agreement dated as of September 1, 2017 with CRG Servicing LLC.
Synergy Pharmaceuticals Announces FDA Approval of TRULANCE (Plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults
Synergy Pharmaceuticals Inc. announced today that the FDA has approved TRULANCE (plecanatide) 3 mg tablet for the once-daily treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
From 1997 through 2013, there was an average of 27 novel drugs approved in the U.S. per year.
12/22/2017Synergy announced that Troy Hamilton, Pharm.D., previously Executive VP, COO, has been appointed CEO, effective immediately.
Biotech companies have a number of pivotal challenges in going from a promising compound to commercially viable products.
Synergy Pharmaceuticals announced the pricing of its underwritten offering of 21,705,426 shares of its common stock together with accompanying warrants to purchase an aggregate of 21,705,426 shares of common stock at a combined price to the public of $2.58 per share and accompanying warrant.
Total net sales were $5.0 million for the third quarter of 2017, a 117.4% increase over the prior quarter.
Synergy Pharmaceuticals to Report Third Quarter 2017 Financial Results and Host Conference Call and Webcast
The Company will host a conference call and webcast to discuss its financial and business results on the same day at 4:30 p.m. ET.
Synergy Pharmaceuticals Presents Results From Study Examining Patient And Physician Perceptions And Experiences With Irritable Bowel Syndrome With Constipation (IBS-C)
Synergy Pharma announced today new findings highlighting the frustration of patients suffering from irritable bowel syndrome with constipation (IBS-C) and the perceptions of healthcare providers (HCPs) who treat these patients.
Synergy Pharma To Highlight New Data For TRULANCE (Plecanatide) At The World Congress Of Gastroenterology (WCOG) At American College of Gastroenterology
Synergy Pharma Announces Acceptance Of Supplemental New Drug Application (sNDA) For TRULANCE (Plecanatide) For The Treatment Of Adults With Irritable Bowel Syndrome With Constipation (IBS-C)
Synergy Pharma To Present Positive TRULANCE (Plecanatide) Phase III Data At Digestive Disease Week (DDW) For The Treatment Of Irritable Bowel Syndrome With Constipation (IBS-C)